Plaintiffs Ask JPML to Consolidate All Testosterone Therapy Drug Litigation

WASHINGTON, D.C. — A couple that is accusing Abbott Laboratories and AbbVie Inc. of concealing cardiovascular risks associated with the testosterone replacement therapy AndroGel is seeking consolidation of litigation involving all testosterone therapy drugs.

In their April 14 motion before the Judicial Panel of Multidistrict Litigation, Rafael and Connie Barrios assert that consolidation in the U.S. District Court for the Eastern District of Louisiana is warranted in light of common questions of fact involved in the actions.

To date, there are 50 cases on file involving various testosterone replacement therapy drugs; nine of these cases involve drugs other than AndroGel, …